IPHA
Innate Pharma·NASDAQ
--
--(--)
--
--(--)
IPHA fundamentals
During FY 2025, Innate Pharma (IPHA) reported revenue of 10.57M, a YoY change of -49.26%. Net income was -57.71M, a YoY change of -12.71%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2017 | H1,2018 | FY,2018 | H1,2019 | FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jan 1, 2017 | Jan 1, 2018 | Jan 1, 2018 | Jan 1, 2019 | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | Jan 1, 2025 | -- |
End Date | Dec 31, 2017 | Jun 30, 2018 | Dec 31, 2018 | Jun 30, 2019 | Dec 31, 2019 | Jun 30, 2020 | Dec 31, 2020 | Jun 30, 2021 | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 52.94M -- | 26.85M -- | 107.63M +103.32% | 67.28M +150.57% | 95.93M -10.87% | 41.29M -38.63% | 85.33M -11.05% | 17.38M -57.90% | 27.96M -67.24% | 47.73M +174.57% | 61.70M +120.68% | 43.90M -8.03% | 68.19M +10.51% | 13.22M -69.88% | 20.83M -69.46% | 5.72M -56.74% | 10.57M -49.26% | 10.57M -- |
Sales and Services Revenue | 52.94M -- | 26.85M -- | 107.63M +103.32% | 67.28M +150.57% | 95.93M -10.87% | 41.29M -38.63% | 85.33M -11.05% | 17.38M -57.90% | 27.96M -67.24% | 47.73M +174.57% | 61.64M +120.45% | 43.90M -8.03% | 68.18M +10.61% | 13.22M -69.88% | 20.82M -69.47% | 5.72M -56.74% | 10.55M -49.30% | 10.55M -- |
Other Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 63.12K -- | -- -- | 12.17K -80.72% | -- -- | 11.39K -6.43% | -- -- | 15.26K +33.99% | 15.26K -- |
Gross Profit | 52.94M -- | 26.85M -- | 107.63M +103.32% | 67.28M +150.57% | 95.93M -10.87% | 41.29M -38.63% | -- -- | 17.38M -57.90% | -- -- | 47.73M +174.57% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 101.00M -- | 44.25M -- | 101.74M +0.73% | 56.53M +27.74% | 94.17M -7.44% | 50.67M -10.36% | 84.01M -10.78% | 40.11M -20.85% | 82.09M -2.29% | 38.83M -3.17% | 123.13M +50.00% | 44.33M +14.16% | 82.20M -33.24% | 41.41M -6.60% | 74.21M -9.72% | 35.65M -13.91% | 73.95M -0.35% | 73.95M -- |
Selling, General and Administrative Expenses | 20.46M -- | 6.51M -- | 20.78M +1.60% | 10.57M +62.37% | 23.55M +13.32% | 16.28M +54.01% | 23.22M -1.41% | 14.98M -8.00% | 28.89M +24.41% | 12.71M -15.15% | 24.00M -16.91% | 9.99M -21.43% | 20.23M -15.71% | 10.26M +2.78% | 20.41M +0.88% | 11.50M +12.01% | 22.76M +11.53% | 22.76M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 23.22M -- | -- -- | 28.89M +24.41% | -- -- | 24.00M -16.91% | 9.99M -- | 20.23M -15.71% | 10.26M +2.78% | -- -- | 11.50M +12.01% | -- -- | -- -- |
Research and Development Expenses | 80.55M -- | 37.74M -- | 79.68M -1.07% | 41.61M +10.25% | 70.61M -11.38% | 35.40M -14.94% | 60.79M -13.91% | 25.13M -29.01% | 53.20M -12.49% | 26.13M +3.98% | 55.27M +3.89% | 34.35M +31.46% | 61.97M +12.13% | 31.14M -9.33% | 53.80M -13.18% | 24.15M -22.45% | 51.19M -4.85% | 51.19M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 43.86M -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Expenses | -- -- | -- -- | 1.27M -- | 4.34M -- | -- -- | -1.01M -123.15% | -- -- | -1.18K +99.88% | -- -- | -1.05K +11.64% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -48.07M -- | -17.40M -- | 5.90M +112.26% | 10.76M +161.81% | 1.77M -70.01% | -9.38M -187.23% | 1.32M -25.37% | -22.72M -142.21% | -54.13M -4201.82% | 8.89M +139.13% | -61.43M -13.50% | -434.62K -104.89% | -14.01M +77.19% | -28.18M -6384.77% | -53.39M -280.93% | -29.93M -6.19% | -63.38M -18.73% | -63.38M -- |
Non-Operating Income (Loss) | -9.66M -- | -642.24K -- | -2.78M +71.21% | 4.30M +770.15% | 7.07M +354.11% | -2.23M -151.83% | -2.33M -133.03% | 2.02M +190.78% | 2.66M +213.84% | -2.22M -209.51% | -585.18K -122.03% | 2.31M +204.21% | 5.64M +1063.89% | 1.66M -28.20% | 2.18M -61.39% | 4.81M +189.65% | 5.67M +160.33% | 5.67M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -675.10K -- | -- -- | 1.22M +281.40% | -- -- | -1.75M -242.57% | 1.14M -- | 1.82M +204.42% | 1.58M +38.20% | -- -- | 546.13K -65.34% | -- -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -1.93M -- | -- -- | 1.41M +173.14% | -- -- | 884.72K -37.36% | 470.65K -- | 1.01M +14.28% | -953.28K -302.54% | -- -- | 3.60M +477.32% | -- -- | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 2.26K -- | -- -- | 0 -100.00% | -- -- | 0 -- | -1.07K -- | -- -- | -1.18K -9.89% | -- -- | -- -- |
Net Interest Expense | 9.66M -- | 642.24K -- | 2.78M -71.21% | -4.30M -770.15% | -7.07M -354.11% | 2.23M +151.83% | -272.73K +96.14% | -2.02M -190.78% | -16.98K +93.78% | 2.22M +209.51% | -276.01K -1525.78% | -699.97K -131.57% | -2.81M -916.79% | -1.04M -48.28% | -2.18M +22.40% | -663.83K +36.04% | -5.67M -160.33% | -5.67M -- |
Interest Expense | 12.67M -- | 5.54M -- | 9.66M -23.76% | 2.20M -60.34% | 5.59M -42.15% | 4.98M +126.47% | 417.04K -92.53% | 2.11M -57.62% | 353.12K -15.33% | 6.46M +205.91% | 308.10K -12.75% | 353.81K -94.52% | 707.97K +129.78% | 321.33K -9.18% | 4.11M +481.17% | 269.53K -16.12% | 3.66M -11.01% | 3.66M -- |
Interest Income | 3.01M -- | 4.90M -- | 6.88M +128.69% | 6.50M +32.65% | 12.65M +84.00% | 2.75M -57.73% | 689.77K -94.55% | 4.13M +50.44% | 370.10K -46.34% | 4.24M +2.49% | 584.11K +57.83% | 1.05M -75.13% | 3.51M +501.67% | 1.36M +28.99% | 6.29M +79.05% | 933.36K -31.33% | 9.33M +48.30% | 9.33M -- |
Pretax Income From Continuing Operations | -57.72M -- | -18.04M -- | 3.11M +105.39% | 15.06M +183.46% | 8.83M +183.69% | -11.61M -177.11% | -1.01M -111.48% | -20.70M -78.25% | -51.47M -4976.80% | 6.68M +132.25% | -62.02M -20.49% | 1.88M -71.89% | -8.37M +86.50% | -26.52M -1513.86% | -51.21M -511.51% | -25.12M +5.29% | -57.72M -12.71% | -57.72M -- |
Income Tax Expense | 442.41K -- | -388.84K -- | -381.48K -186.23% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Income from Discontinued Operations | -- -- | -- -- | -- -- | -- -- | -32.14M -- | -- -- | -77.24M -140.32% | -7.40M -- | -8.30M +89.26% | -76.42K +98.97% | -140.14K +98.31% | -- -- | 0 +100.00% | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Other Items Before Net Income | -1.20K -- | 1.17K -- | -2.29K -90.58% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -58.17M -- | -17.65M -- | 3.49M +106.00% | 15.06M +185.31% | -23.31M -767.24% | -11.61M -177.11% | -78.25M -235.76% | -28.10M -142.00% | -59.77M +23.62% | 6.60M +123.48% | -62.16M -4.00% | 1.88M -71.57% | -8.37M +86.53% | -26.52M -1513.86% | -51.21M -511.51% | -25.12M +5.29% | -57.71M -12.71% | -57.71M -- |
Net Income Attributable to Owners of the Company | -58.17M -- | -17.65M -- | 3.49M +106.00% | 15.06M +185.31% | -23.31M -767.24% | -11.61M -177.11% | -78.25M -235.76% | -28.10M -142.00% | -59.77M +23.62% | 6.60M +123.48% | -62.16M -4.00% | 1.88M -71.57% | -8.37M +86.53% | -26.52M -1513.86% | -51.21M -511.51% | -25.12M +5.29% | -57.71M -12.71% | -57.71M -- |
Net Income Attributable to Common Stockholders | -58.17M -- | -17.65M -- | 3.49M +106.00% | 15.06M +185.31% | -23.31M -767.24% | -11.61M -177.11% | -78.25M -235.76% | -28.10M -142.00% | -59.77M +23.62% | 6.60M +123.48% | -62.16M -4.00% | 1.88M -71.57% | -8.37M +86.53% | -26.52M -1513.86% | -51.21M -511.51% | -25.12M +5.29% | -57.71M -12.71% | -57.71M -- |
Other Comprehensive Income | 821.10K -- | -1.15M -- | -716.00K -187.20% | -906.51K +21.03% | 703.93K +198.31% | -161.81K +82.15% | 26.91K -96.18% | 459.70K +384.10% | 114.31K +324.86% | -208.33K -145.32% | 387.27K +238.78% | 269.72K +229.47% | 741.15K +91.38% | -151.03K -155.99% | -- -- | 1.37M +1010.27% | -- -- | -- -- |
Total Comprehensive Income | -57.35M -- | -18.80M -- | 2.78M +104.84% | 14.15M +175.28% | -22.60M -913.93% | -11.77M -183.19% | -78.23M -246.10% | -27.64M -134.77% | -59.65M +23.74% | 6.39M +123.12% | -61.77M -3.55% | 2.15M -66.42% | -7.63M +87.64% | -26.68M -1343.17% | -- -- | -23.75M +10.98% | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -57.35M -- | -18.80M -- | 2.78M +104.84% | 14.15M +175.28% | -22.60M -913.93% | -11.77M -183.19% | -78.23M -246.10% | -27.64M -134.77% | -59.65M +23.74% | 6.39M +123.12% | -61.77M -3.55% | 2.15M -66.42% | -7.63M +87.64% | -26.68M -1343.17% | -- -- | -23.75M +10.98% | -- -- | -- -- |
Basic EPS | -1.07 -- | -0.3 -- | 0.06 +105.61% | 0.24 +180.00% | -0.35 -683.33% | -0.15 -162.50% | -0.99 -182.86% | -0.36 -140.00% | -0.75 +24.24% | 0.08 +122.22% | -0.78 -4.00% | 0.02 -75.00% | -0.1 +87.18% | -0.33 -1750.00% | -0.63 -530.00% | -0.29 +12.12% | -0.65 -3.17% | -0.65 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | 0.13 -- | -- -- | -0.01 -107.69% | -- -- | -0.65 -6400.00% | 0.08 -- | -0.78 -20.00% | 0.02 -75.00% | -0.1 +87.18% | -0.33 -1750.00% | -0.63 -530.00% | -0.29 +12.12% | -0.65 -3.17% | -0.65 -- |
Basic EPS from Discontinued Operations | -- -- | -- -- | -- -- | -- -- | -0.48 -- | -- -- | -0.98 -104.17% | -- -- | -0.1 +89.80% | -- -- | 0 +100.00% | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Diluted EPS | -1.07 -- | -0.3 -- | 0.06 +105.61% | 0.23 +176.67% | -0.35 -683.33% | -0.15 -165.22% | -0.99 -182.86% | -0.36 -140.00% | -0.75 +24.24% | 0.08 +122.22% | -0.78 -4.00% | 0.02 -75.00% | -0.1 +87.18% | -0.33 -1750.00% | -0.63 -530.00% | -0.29 +12.12% | -0.65 -3.17% | -0.65 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | 0.13 -- | -- -- | -0.01 -107.69% | -- -- | -0.65 -6400.00% | 0.08 -- | -0.78 -20.00% | 0.02 -75.00% | -0.1 +87.18% | -0.33 -1750.00% | -0.63 -530.00% | -0.29 +12.12% | -0.65 -3.17% | -0.65 -- |
Diluted EPS from Discontinued Operations | -- -- | -- -- | -- -- | -- -- | -0.48 -- | -- -- | -0.98 -104.17% | -- -- | -0.1 +89.80% | -- -- | 0 +100.00% | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
You can ask Aime
What does Innate Pharma do and what are its main business segments?What is Innate Pharma's gross profit margin?What were the key takeaways from Innate Pharma's earnings call?What is the revenue and EPS growth rate for Innate Pharma year over year?What factors drove the changes in Innate Pharma's revenue and profit?What is the market's earnings forecast for Innate Pharma next quarter?What were the key takeaways from Innate Pharma’s earnings call?What is Innate Pharma's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
